National Academies Press: OpenBook
« Previous: Appendix B: Agendas for Information-Gathering Meetings
Suggested Citation:"Appendix C: Acknowledgements." Institute of Medicine and National Research Council. 2004. Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents. Washington, DC: The National Academies Press. doi: 10.17226/10908.
×
Page 127
Suggested Citation:"Appendix C: Acknowledgements." Institute of Medicine and National Research Council. 2004. Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents. Washington, DC: The National Academies Press. doi: 10.17226/10908.
×
Page 128
Suggested Citation:"Appendix C: Acknowledgements." Institute of Medicine and National Research Council. 2004. Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents. Washington, DC: The National Academies Press. doi: 10.17226/10908.
×
Page 129
Suggested Citation:"Appendix C: Acknowledgements." Institute of Medicine and National Research Council. 2004. Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents. Washington, DC: The National Academies Press. doi: 10.17226/10908.
×
Page 130

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

APPENDIX C Acknowledgments T he committee is grateful to the following individuals who provided information and assistance to the study through presentations or par- ticipation at meetings and workshops, informal meetings, or other means. Affiliations listed are those at the time of the individual's first con- tact with the committee. Vivian Albert, Ph.D., Vice President, Preclinical Research and Development, Human Genome Sciences Penrose (Parney) Albright, Ph.D., Senior Advisor, Science and Technology Directorate, Department of Homeland Security Maria Bernwinkler, Director, Clinical Research, PPD LTC Robert Borowski, Ph.D., Senior Medical Advisor, Office of the Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense COL W. Neal Burnette, Ph.D., Assistant Joint Program Executive Officer, Medical Systems, Joint Program Executive Office for Chemical and Biological Defense Programs John Carney, Ph.D., Unconventional Pathogen Countermeasures Program, Defense Advanced Research Projects Agency Salvatore Cirone, D.V.M., M.P.V.M., Program Director, Health Science Policy, Force Health Protection and Readiness, Office of the Assistant Secretary of Defense (Health Affairs) LTC Edward Clayson, Ph.D., Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense 127

128 GIVING FULL MEASURE TO COUNTERMEASURES COL David Danley, Ph.D., Director, Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense David Edman, Ph.D., Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense William Egan, Ph.D., Deputy Director, Office of Vaccines Research and Review, Food and Drug Administration Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases Richard Fieldhouse, Professional Staff Member, Senate Armed Services Committee MAJ Ronald Fizer, Joint Requirements Integrator, Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense Joan Fusco, Ph.D., Vice President, Technical Affairs, Baxter Vaccines Karen Goldenthal, M.D., Director, Division of Vaccines and Related Products Applications, Center for Biologics Evaluation and Research, Food and Drug Administration Jesse Goodman, M.D., M.P.H., Director, Center for Biologics Evaluation and Research, Food and Drug Administration Christine Grant, J.D., M.B.A., Vice President, Public Policy and Government Relations, Aventis Pasteur Carole Heilman, Ph.D., Director, Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases COL Erik Henchal, Ph.D., Commander, U.S. Army Medical Research Institute of Infectious Diseases Stephen Hoffman, M.D., Chief Executive and Scientific Officer, Sanaria Inc. COL Charles Hoke, Jr., M.D., U.S. Army Medical Research and Materiel Command Terry Irgens, President, DynPort Vaccine Company LLC Leonard Izzo, Technical Director, Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense Virginia Johnson, Ph.D., Vice President for Regulatory Affairs, DynPort Vaccine Company LLC Anna Johnson-Winegar, Ph.D., Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense Raymond Keifer, Ph.D., Senior Director Manufacturing, BioReliance Corporation Lawrence Kerr, Ph.D., Assistant Director for Homeland Security, Office of Science and Technology Policy Dale Klein, Ph.D., Assistant to the Secretary of Defense for Nuclear and Chemical and Biological Defense

APPENDIX C 129 Rudy Kuppers, Ph.D., SAIC Support Contractor, Military Infectious Diseases Research Program, U. S. Army Medical Research and Materiel Command Jeffrey Kushan, J.D., Partner, Sidley Austin Brown and Wood Michael J. Langford, D.V.M., Ph.D., Senior Vice President and Chief Scientific Officer, DynPort Vaccine Company LLC Frank Lee, Ph.D., President and CEO, engeneOS Brad Leissa, M.D., Deputy Director, Division of Counterterrorism, Center for Drug Evaluation and Research, Food and Drug Administration Stanley Lemon, M.D., Dean of Medicine and Professor, University of Texas Medical Branch, Galveston Carol Linden, Ph.D., Director, Medical Chemical and Biological Defense Research Program, U.S. Army Medical Research and Materiel Command Chuck Ludlam, J.D., Counsel, Office of Senator Joseph Lieberman MG Lester Martinez-Lopez, M.D., Commander, U.S. Army Medical Research and Materiel Command Mark B. McClellan, M.D., Ph.D., Commissioner, Food and Drug Administration John McCormick, M.D., Orphan Products Development, Food and Drug Administration Andrea Meyerhoff, M.D., Director, Counterterrorism Programs, Office of the Commissioner, Food and Drug Administration Alan B. Morrison, LL.B., Public Citizen Litigation Group Dianne Murphy, M.D., Director, Office of Counterterrorism and Pediatric Drug Development, Center for Drug Evaluation and Research, Food and Drug Administration Col Joseph Palma, M.D., M.P.H., Chief Medical Advisor, Office of the Deputy Assistant to the Secretary of Defense for Chemical and Biological Defense Dennis Panicali, Ph.D., Chief Scientific Officer, Therion Biologics COL Gerald Parker, M.S., D.V.M., Ph.D., Assistant Deputy for Research and Development, U.S. Army Medical Research and Materiel Command Vicki Pierson, Ph.D., Biodefense Projects Manager, Office of Biodefense Research Affairs, National Institute of Allergy and Infectious Diseases Rick Prouty, Medical Action Officer, Joint Requirements Office for Chemical, Biological, Radiological, and Nuclear Defense Gerald V. Quinnan, Jr., M.D., Professor and Chair of Preventive Medicine, Uniformed Services University of the Health Sciences

130 GIVING FULL MEASURE TO COUNTERMEASURES Jean Reed, Professional Staff Member, House Armed Services Committee BG Stephen Reeves, Program Executive Officer, Chemical and Biological Defense Philip Russell, M.D., Office of Emergency Preparedness Planning, Department of Health and Human Services Jerald Sadoff, M.D., Washington, DC Lynn Selfridge, Chemical Biological Medical Systems, Joint Program Executive Office for Chemical and Biological Defense Leonard Smith, Ph.D., Department of Immunology and Molecular Biology, Division of Toxicology, U.S. Army Medical Research Institute of Infectious Diseases John D. Strandberg, D.V.M., Ph.D., Director, Division of Comparative Medicine, National Center for Research Resources, National Institutes of Health COL David Vaughn, M.D., M.P.H., Research Area Director, Military Infectious Diseases Research Program, U.S. Army Medical Research and Materiel Command LTC Keith R. Vesely, D.V.M., Ph.D., Chief, Medical Science and Technology Division, Chemical and Biological Defense Directorate, Defense Threat Reduction Agency Judith Wagner, Ph.D., Scholar in Residence, Institute of Medicine Jay Winchester, Office of the Staff Judge Advocate, U.S. Army Medical Research and Materiel Command William Winkenwerder, Jr., M.D., M.B.A., Assistant Secretary of Defense for Health Affairs Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, Food and Drug Administration Peter Young, M.B.A., President and CEO, AlphaVax Philip Youngman, Ph.D., Vice President of Discovery Biology, Elitra Pharmaceuticals Kathryn Zoon, Ph.D., Director, Center for Biologics Evaluation and Research, Food and Drug Administration

Next: Appendix D: Biographical Sketches »
Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents Get This Book
×
 Giving Full Measure to Countermeasures: Addressing Problems in the DoD Program to Develop Medical Countermeasures Against Biological Warfare Agents
Buy Paperback | $44.00 Buy Ebook | $35.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

In recent years, substantial efforts have been initiated to develop new drugs, vaccines, and other medical interventions against biological agents that could be used in bioterrorist attacks against civilian populations. According to a new congressionally mandated report from the Institute of Medicine and National Research Council of the National Academies, to successfully develop these drugs, vaccines, and other medical interventions against biowarfare agents, Congress should authorize the creation of a new agency within the Office of the Secretary of the U.S. Department of Defense. The committee recommended that Congress should improve liability protections for those who develop and manufacture these products, to stimulate willingness to invest in new research and development for biowarfare protection. Giving Full Measure to Countermeasures also identifies other challenges—such as the need for appropriate animal models and laboratories equipped with high-level biosafety protections—that will require attention if DoD efforts to develop new medical countermeasures are to be successful.

READ FREE ONLINE

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!